Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MetaStat Inc (MTST)
Boston, MA, US
MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company’s therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +66.67% | +66.67% | +233.33% | +66.67% | +900.00% | +900.00% | -96.30% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Electrical Equipment & Parts: +13.1%—
-
EPS growth Electrical Equipment & Parts: +22.4%+40.4% ★ Q1'18: +45.2% (vs Q1'17)
-
FCF margin FCF growth · Electrical Equipment & Parts: +27.2%-14,749.4%
-
EBIT margin Electrical Equipment & Parts: +8.2%-12,625.9%
-
ROIC Electrical Equipment & Parts: +6.4%— Q1'18: +421.3% (vs Q1'17)
-
Share dilution Electrical Equipment & Parts: +0.0%+82.9% Q1'18: +81.0% (vs Q1'17)
-
Debt / EBITDA Net debt/EBITDA · Electrical Equipment & Parts: -0.54×-0.29× Q1'18: -0.29× (vs Q1'17)
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-01-12 | Schneiderman Daniel H | Officer | J-Other | A | Options to purchase Common Stock | 76,962 | 0.93 | 71.6K | 76,962 | — | ↗ |
| 2017-10-11 | ZELDIS JEROME B | Director | M-Exempt | A | Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2017-10-11 | Billings Paul | Director | M-Exempt | A | Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2017-05-24 | Billings Paul | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-08-05 | Driscoll Martin J | Director | P-Purchase | A | Common Stock | 4,100 | 0.27 | 1.1K | 19,100 | — | ↗ |
| 2015-06-25 | Driscoll Martin J | Director | P-Purchase | A | Common Stock | 10,000 | 0.35 | 3.5K | 10,000 | — | ↗ |
| 2015-06-18 | Bronsther Oscar | Director | P-Purchase | A | Stock Options | 400,000 | 0.55 | 220.0K | 400,000 | — | ↗ |
| 2015-05-18 | Spoor Johan M. | Director | A-Award | A | Stock Options | 300,000 | 0.39 | 117.0K | 0 | — | ↗ |
| 2015-05-18 | Driscoll Martin J | Director | A-Award | A | Stock Options | 300,000 | 0.55 | 165.0K | 300,000 | — | ↗ |
| 2015-05-18 | BERMAN RICHARD J | Director | A-Award | A | Stock Options | 300,000 | 0.39 | 117.0K | 300,000 | — | ↗ |
| 2015-03-31 | Driscoll Martin J | Director | — | D | Series B Preferred Stock | 90,909 | 0.55 | 50.0K | 0 | — | ↗ |
| 2015-03-27 | BERMAN RICHARD J | Director | P-Purchase | A | Series B Convertible Preferred Stock | 9 | 0.55 | 5.00 | 9 | — | ↗ |
| 2014-12-31 | Spoor Johan M. | Director | P-Purchase | A | Series A Common Stock Purchase Warrants | 22,500 | 0.70 | 15.8K | 22,500 | — | ↗ |
| 2014-12-31 | Bronsther Oscar | Director / Officer | P-Purchase | A | Series A Common Stock Purchase Warrants | 34,091 | 0.70 | 23.9K | 34,091 | — | ↗ |
| 2014-10-15 | BERMAN RICHARD J | Director | — | D | Common Stock | 0 | 0.00 | — | 64,935 | — | ↗ |
| 2014-10-14 | Spoor Johan M. | Director | A-Award | A | Common Stock | 104,935 | 0.00 | — | 369,603 | — | ↗ |
| 2014-10-14 | Schneiderman Daniel H | Officer | A-Award | A | Options to purchase Common Stock | 300,000 | 1.10 | 330.0K | 300,000 | — | ↗ |
| 2014-10-14 | SIEGEL DAVID N | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 90,000 | — | ↗ |
| 2014-10-14 | Epstein David M. | Director | A-Award | A | Common Stock | 104,935 | 0.00 | — | 217,435 | — | ↗ |
| 2014-07-22 | Spoor Johan M. | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 264,668 | — | ↗ |
| 2014-07-22 | SIEGEL DAVID N | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 777,500 | — | ↗ |
| 2014-07-22 | Epstein David M. | Director | A-Award | A | Common Stock | 12,500 | 0.00 | — | 112,500 | — | ↗ |
| 2014-07-14 | Epstein David M. | Director | A-Award | A | Common Stock | 188,182 | 1.10 | 207.0K | 188,182 | — | ↗ |
| 2014-06-30 | SIEGEL DAVID N | Director | P-Purchase | A | Warrants to purchase Common Stock | 75,000 | 1.50 | 112.5K | 75,000 | — | ↗ |
| 2014-06-30 | Epstein David M. | Director | A-Award | A | Common Stock | 39,091 | 1.10 | 43.0K | 227,223 | — | ↗ |
| 2013-04-16 | Epstein David M. | Director | — | D | Common Stock | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2013-04-09 | Spoor Johan M. | Director | A-Award | A | Common Stock | 150,000 | 0.00 | — | 214,668 | — | ↗ |
| 2013-04-05 | Schneiderman Daniel H | Officer | A-Award | A | Options to purchase Common Stock | 50,000 | 3.25 | 162.5K | 50,000 | — | ↗ |
| 2013-04-05 | SIEGEL DAVID N | Director | A-Award | A | Options to purchase Common Stock | 50,000 | 3.25 | 162.5K | 50,000 | — | ↗ |
| 2013-04-05 | Bronsther Oscar | Director / Officer | A-Award | A | Options to purchase Common Stock | 100,000 | 3.25 | 325.0K | 100,000 | — | ↗ |
| 2013-02-28 | SIEGEL DAVID N | Director | P-Purchase | A | Common Stock | 150,000 | 1.00 | 150.0K | 727,500 | — | ↗ |
| 2012-12-21 | Schneiderman Daniel H | Officer | — | D | Common Stock | 0 | 0.00 | — | 357,500 | — | ↗ |
| 2012-05-22 | Spoor Johan M. | Director | A-Award | A | Common Stock | 50,000 | 0.00 | — | 64,668 | — | ↗ |
| 2012-01-06 | Schneiderman Daniel H | Officer | — | D | Options | 55,000 | 0.68 | 37.4K | 0 | — | ↗ |
| 2011-11-14 | Schneiderman Daniel H | Officer | — | D | Warrants | 22,000 | 0.68 | 15.0K | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Frederick E. Pierce | Vice President of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MTST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
